Kornimate/medical-research-clean huggingface dataset:
mechanisms for atrial fibrillation in obstructive sleep apnea

Conditions: Atrial Fibrillation; Obstructive Sleep Apnea; Hypertension; Autonomic Dysfunction; Arterial Stiffness

Summary: atrial fibrillation (af) is the most common rhythm disorder and involves an increased risk of cardiovascular disease and death, impaired quality of life and a high proportion of healthcare consumption. an important risk factor is obstructive sleep apnea (osa). however, it is not fully understood why osa induces af. it may be due to a proinflammatory state, sympathetic activation and acute changes in blood pressure during apnéas, but few studies are performed. hypertension with its coherent arterial stiffness is related to all these factors, is common in osa, and is the most common cause of af. the cause of af in hypertensive subjects is believed due to a pressure overloaded left heart, with dilation and fibrosis of the left atrium, promoting the development of af. hypertension and arterial stiffness can thus be important triggering factors for af in osa. in this project, teh investigators investigate the occurrence of osa in af patients. furthermore, underlying mechanisms for the development and recurrence of af after intervention in osa patients are investigated. 300 patients scheduled for af ablation or cardioversion are invited and examined with sleep registration, 24h blood pressure, aortic stiffness measurement, test of autonomic function, echocardiography, ecg and labs. the patients are followed at months 3, 6 and 12 with 7 days ecg for recurrence. the aim is to give insights into the need for screening for osa in patients with af. the study also aim at enabling preventive treatment through better understanding of underlying treatable mechanisms. the results are believed to lead to fewer new afs, as well as fewer af recurrences in patients with osa.


Eligibility criteria:
inclusion criteria: * patients \>18 years scheduled for af ablation or cardioversion exclusion criteria: diagnosis of af for more than 7 years * previous cardiac surgery including af ablation * severe valvular heart disease * diagnosed structural heart disease * systolic function in sinus rhythm \<50%. * severe hypertensive heart disease or known hypertrophic heart disease (amyloidosis, hereditary hypertrophic heart disease) * invalidating chronic diseases imaging material on echocardiography not of sufficient quality.
clinical trials of ct-guided percutaneous irreversible electroporation（ire）in the treatment of patients with locally advanced tumors

Conditions: Neoplasms; Carcinoma

Summary: irreversible electroporation (ire) is an emerging nonthermal focal ablation technique that uses a series of short but intense electric pulses delivered by nanoknife generator through paired electrodes into a targeted region of tissue, inducing the cells death by apoptosis through irreversibly disrupting cellular membrane integrity. this study aimed to investigate the safety and efficacy of ct-guided percutaneous irreversible electroporation（ire） in the treatment of patients with locally advanced tumors in different anatomical position.

this study is a multicenter, open-label trial that aimed to evaluate the safety and efficacy of ct-guided percutaneous irreversible electroporation（ire）in the treatment of patients with locally advanced tumors. investigators will screen eligible patients and examine them by imaging tests as well as serological examination before and after the ire procedures to assess the result with the size，blood supply，metabolism of tumors，the change of blood test and treatment-related complications. big bore multislice spiral ct with thickness 5 cm, 120kilovolt，and 250milliampere，ecg-gated device and anesthesia monitoring equipment were selected during these procedures. imaging (performed by contrast enhanced ct scan) and serological follow-up was at postoperative day 3 and 1，3，6，12months. the primary endpoint is the effective rate of ire，and the secondary endpoint is 1-year survival rate and the frequency of adverse events. the response of irreversible electroporation ablation will be assessed according to the different evaluation criterions based on response evaluation criteria in solid tumors.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed locally advanced solid tumor. 2. unresectable tumors or the patient refused surgical therapy. 3. patients in good health conditions can receive general anesthesia. 4. patients with good compliance can cooperate with doctors for related tests and the regular follow-up. exclusion criteria: 1. targeted tissues that metallic wallstents or metallics were implanted. 2. with heart pacemaker or be allergic to contrast medium that can not have related imaging examinations. 3. with bleeding and psychiatric disorders. 4. severe arrhythmia.

Keywords: irreversible electroporation ablation neoplasms cancer carcinoma nanoknife ablation techniques
evaluation of the accuracy of the vessel navigator tool for catheterization of supra-aortic vessels - archibald

Conditions: Vascular Diseases; Cerebrovascular Diseases; Cardiovascular Diseases; Aortic Aneurysm; Arteriovenous Malformation

Summary: this study compares the accuracy of fusion imaging (fusion roadmap) versus real-time x-ray imaging (roadmap) during catheterization of supra-aortic trunks of in patients with aneurysms or arteriovenous malformations.

catheterization of is performed for the diagnosis and treatment of cerebrovascular diseases. it is performed under x-ray scopy in frontal incidence with possible variations of the angulation of the arch to optimize the visualization of vessels 'origin (brachiocephalic trunk, left and right common carotid arteries, subclavian arteries). before the beginning of catheterization, a conventional arterial roadmap with iodine injection is usually performed. the vessel navigator (vn) developed by philips allows the use of pre-acquired angio-scan or angio-mri image by superimposing it (x-ray fusion) on x-ray scopy to provide the arterial tracing (fusion roadmap). an angio-mri (philips 3 tesla mri) imaging of the aortic arch will be first performed (as part of preoperative assessment or systematic follow-up of aneurysms or arteriovenous malformations). a first operator will perform the arteriography under the usual conditions without using the vn. a second operator will have access to the fusion imaging and will assess the accuracy of the coregistration. snapshots will be taken by the second operator.

Eligibility criteria:
inclusion criteria: * preoperative assessment or systematic follow-up of aneurysms or arteriovenous malformations, arterial cervical or intracranial stenosis, head and neck vascular tumors. exclusion criteria: * patients with contraindication to intravenous contrast. * patients with catheterization of the supra-aortic vessels in an emergency settings (stroke, acute bleeding)

Keywords: vascular diseases cerebrovascular diseases cardiovascular diseases aortic aneurysm arteriovenous malformations catheterization
cyt003-qbg10 for treatment of allergic asthma bronchial

Conditions: Allergic Bronchial Asthma

Summary: the purpose of the study is to test whether treatment with cyt003-qbg10 can improve asthma symptoms in patients with allergic bronchial asthma. the active treatment will be compared against placebo.


Eligibility criteria:
inclusion criteria: * persistent allergic asthma bronchial requiring long-term treatment with inhaled corticosteroids * further criteria as defined in the study protocol exclusion criteria: * use of oral corticosteroids within past 3 months * hospitalization for asthma exacerbation within past 6 months * uncontrolled asthma * contraindication to any study test or procedure * further criteria as defined in the study protocol
assessing the safety/efficacy of transdermal testosterone in female patients with symptomatic heart failure

Conditions: Heart Failure

Summary: heart failure (hf) is a complex condition resulting from structural or functional heart diseases that impair the ability of the heart to fill with or pump out blood. the main manifestations of hf are shortness of breath and tiredness which may limit the ability to exercise or perform simple daily physical activities such as walking. heart disease leading to hf is associated with reduced muscle mass and reduced strength and low blood levels of testosterone; a hormone normally produced by the human (male and female) body. recent studies have shown improvements of symptoms and ability to exercise in patients with heart failure receiving testosterone. this is a placebo controlled study to determine the efficacy and safety of low dose testosterone (300 and 450 microgram/day) delivered by a transdermal system (patch) in women with significant hf.


Eligibility criteria:
inclusion criteria: * female 50 years of age or older; post-menopausal (≥ 12 mo/ from last menstruation) * documented left ventricular ejection fraction (lvef) of 20-40% within 90 days prior to the baseline visit * history of hf for more than 90 days and a diagnosis of symptomatic hf (class iii nyha) for at least 30 days prior to the baseline visit * ambulatory (i.e., able to walk without assistance of another person or device such as cane or walker) exclusion criteria: * neuromuscular or rheumatologic conditions that limit the to their ability to improve walking distance * pulmonary edema or multiorgan failure or cardiogenic shock within 30 days prior to the baseline visit * congenital heart disease, infiltrative myocardial disease * unstable angina or myocardial infarction within 30 days prior to the baseline visit * undiagnosed abnormal genital bleeding * history of breast cancer, breast surgery, or breast disease contraindicating estrogen/hormone therapy * polycystic ovary syndrome or any other condition known to be adversely affected by testosterone treatment * resting heart rate \> 120 bpm * systolic blood pressure \> 180 mmhg or diastolic blood pressure \> 100 mmhg * known or suspected hypersensitivity or allergy to any adhesive or to any of the components of the testosterone transdermal system (tts) * use of serms, sarms, sprms, tibolone, testosterone, estrogen, progesterone agonists and antagonists or taking any prescription and over the counter medications/ nutraceuticals (eg, phyto-estrogens) that may have anabolic or steroid hormonal effects within 30 days prior to the baseline visit * use of marketed or investigational oral, sub-lingual, topical, transdermal injectable, or vaginal androgen therapy including dehydroepiandrosterone (dhea) at any time within 3 months prior to the baseline visit * use of systemic corticosteroids within 30 days prior to the baseline visit (acute use for fewer than 7 days is acceptable)
treatment of anemic patients with cancer who are not receiving chemotherapy or radiotherapy

Conditions: Anemia; Cancer

Summary: the purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * body weight \>/= 99lbs * ecog 0-2 * anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy * screening hemoglobin level of \</= 11.0 g/dl for men or \</= 10.0 for women exclusion criteria: * history of or concurrent second malignancy * evidence of primary or metastatic malignancy involving the central nervous system

Keywords: anemia cancer
azithromycin for meningococcal carriage

Conditions: Meningococcal Infections

Summary: the purpose of this study is to determine the effectiveness of azithromycin in the eradication of nasopharyngeal carriage of n. meningitidis

azithromycin belongs to the class of antimicrobials known as macrolides. they are approved for the treatment of a wide variety of infections, including community-acquired respiratory tract infections and sexually transmitted infections caused by different bacteria. their mechanism of action is dependent on bacterial ribosomal binding, leading to inhibition of bacterial protein synthesis. azithromycin has a broad spectrum of activity to include gram-positive and gram-negative organisms, as well as atypical and mycobacterial organisms. a single oral dose of 500mg of azithromycin has been shown to eradicate n. meningitidis colonization. historically, azithromycin has not been recommended as first-line chemoprophylaxis for close contacts of patients with invasive meningococcal disease (imd) since it has not been well studied for this indication. a study from 2020 evaluated the activity of azithromycin against 205 invasive n. meningitidis isolates and found that 100% were susceptible according to clinical and laboratory standards institute (clsi) breakpoints. moreover, with the rise in cases of meningococcal disease caused by ciprofloxacin-resistant strains, the centers for disease control and prevention (cdc) recently updated their guidance to health department for when to consider other options (including azithromycin). participants identified as carriers of n. meningitidis will be asked to take a one-time oral dose of azithromycin, 500mg (standard dose).

Eligibility criteria:
inclusion criteria: * able to provide their own informed consent and understand study procedures * undergraduate and graduate students attending emory university affiliated campuses who reside in university affiliated housing (for undergraduate/graduate) or in off-campus housing (undergraduates). exclusion criteria: * university faculty and staff * currently pregnant or breast feeding * history of immediate or moderate-to-severe allergic reactions to azithromycin * individuals who have taken systemic antibiotics for any reason in the 30 days prior to enrollment * individuals with any symptoms of acute illness at the time of screening
translation and validation of the visual analysis of swallowing efficiency and safety into european portuguese

Conditions: Deglutition Disorders; Deglutition

Summary: the goal of this observational study is to translate and validate to european portuguese "visual analysis of swallowing efficiency and safety - vases".


Eligibility criteria:
inclusion criteria: * patient's fees recording that allowed good visualization of the pharynx and larynx; * fees recording from patients after head and neck surgery who had structural alterations but still did not interfere with a clear visualization of the residues. * patient's tracheostomized or under enteral nutrition. exclusion criteria: * under 18 years of age

Keywords: dysphagia instrumental assessment swallowing disorders fiberoptic endoscopic evaluation of swallow
comparison of nipple-areolar complex sensation according to incision types in nipple-sparing mastectomy

Conditions: Breast Cancer; Nipple Sparing Mastectomy

Summary: this study aims to assess nipple areolar complex sensation after nipple sparing mastectomy and compare the results according to different incisional approaches; specifically, inframammary fold (imf) versus peri-areolar/radial. one-hundred-and-five post nsm patients from oct 2019 to nov 2021 have been recruited prospectively and evaluated for nac sensory. a total of 97 patients (imf 65 and peri-areolar/radial 32) were included in the analyses for comparison during follow up from 24 to 48 months after surgery. it was hypothesized that patients with imf would have better outcomes for nac senroy.


Eligibility criteria:
inclusion criteria: 1. females who are older than 18 2. patients who underwent nipple sparing mastectomy in gangnam severance hospital exclusion criteria: 1. loss or excision of nac due to post-surgical necrosis 2. diagnosis of other conditions that may interfere with cutaneous sensation

Keywords: nac sensory mastectomy nsm
relevance of isoniazid dosage in adults treated for tuberculosis

Conditions: Tuberculosis

Summary: tuberculosis is the third leading infectious killer. in 2021, an estimated 10,6 million people fell ill with tuberculosis worldwide. drug resistance emerges with the increase of antibiotherapy use. among the four antimicrobial drugs used for tuberculosis, isoniazid is a first line treatment. it has a bactericidal activity against the tuberculosis complex. nevertheless, the hepatic metabolism of isoniazid shows variation between individuals. there is a real risk of hepatotoxicity and neurotoxicity induced by isoniazid. the peak measurement (cmax) of serum isoniazid is recommended to adjust the treatment and to allow recovery. moreover, several samples allow a kinetics of isoniazid elimination so as to distinguish slow and fast acetylators. few data are available on isoniazid acetylation. it could be useful to know the proportion of patients treated by isoniazid at a standard dose, associated with a risk of overdosing or underdosing. inadequate exposures should be studied to understand if there is an impact in the medical care.


Eligibility criteria:
inclusion criteria: * to be an adult, * to have a diagnosis of tuberculosis exclusion criteria: * pregnancy, * disagreement to participate

Keywords: isoniazid tuberculosis acetylation
pacareg: a multicenter registry trial in pancreatic ductal adencarcinoma

Conditions: Pancreas Adenocarcinoma; Pancreas Cancer

Summary: pacareg is a multicenter registry trial aiming in the assessement of clinical, epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma


Eligibility criteria:
inclusion criteria: * treatment naive histologically or cytologically proven pancreatic ductal adenocarcinoma (pdac) or highly suspicious diagnosis (only pre-curative-intended resection) * age =\>18 years * written informed consent exclusion criteria: * papillary cancer * neuroendocrine pancreatic tumors
reassure av registry

Conditions: Sudden Cardiac Death; Bradycardia

Summary: long term follow-up to monitor safety for patients implanted with a b301 assure device.

the guidant assure device is a fully featured pacemaker with additional atrial and ventricular tachyarrhythmia therapy features. the reassure av study is a clinical evaluation to support approval of these features. this clinical study is intended to provide adequate performance data on two atrial tachyarrhythmia management features, namely the ats and atrial atp. in addition data will be collected to verify that the ventricular tachyarrhythmia rescue shock feature performs as intended in the clinical setting in combination with other pacemaker functions.

Eligibility criteria:
inclusion criteria: * the patient is willing and capable of providing informed consent at an approved clinical investigational center, and able to attend the investigational center as required by the protocol * patient is implanted with an investigational b301 device as part of the reassure av study exclusion criteria: \* none
5% topical ibuprofen (ibu) for ankle sprain

Conditions: Ankle Injuries

Summary: this study is being conducted to evaluate the effects of ibu 5% topical gel versus topical placebo for the relief of pain associated with a first or second degree ankle sprain. both twice daily and three times daily regimens will be evaluated.


Eligibility criteria:
inclusion criteria: * first or second degree ankle sprain within 48 hours of first dose of study medication * medically cleared to participate exclusion criteria: * similar injury of same joint within last 6 months * requires bed rest, surgery, or over-the-counter or prescription analgesics

Keywords: topical ibuprofen ankle sprain
artificial intelligence - sars-cov-2 (covid-19) risk evaluation

Conditions: Covid19

Summary: the management of covid-19 patients in overwhelmed hospital facing the pandemic is a clinical challenge. the improvement of decision making may allow a better allocation of available resources and a better treatment of patients at higher risk. chest ct has been widely adopted for covid-19 pneumonia diagnosis. several experiences documented the capability of artificial intelligence to improve and fasten covid-19 pneumonia detection, mainly using chest x-ray. aim of the present study was to develop and validate an artificial intelligence approach integrating clinical and imaging data (automatically extracted through the adoption of dedicated neural networks) for the creation of a cloud platform capable of performing automatic patients risk stratification. such an approach could be used for triage of covid-19 patients in the emergency department, with the aim to improve healthcare personnel decision-making and allocation of resources during health emergencies.


Eligibility criteria:
inclusion criteria: * confirmed sars-cov-2 infection with rt-pcr * non contrast chest ct scan performed within 72 hours after admission to the emergency department exclusion criteria: * age \< 18 ys

Keywords: artificial intelligence covid19 chest ct
superficial cryotherapy versus microneedling in alopecia areata

Conditions: Alopecia Areata

Summary: this study is randomized comparative analytical prospective study that included patients with mild and moderate alopecia areata. patients was divided into two groups patients in the first group underwent superficial cryotherapy using dimethyl ether and propane (dmep) at -57c (cryotherapy group). patients in the second group underwent microneedling (microneedling group). a total of six sessions were done at 2 weeks interval. patients were followed-up for next 3 months to evaluate the persistence of hair regrowth after therapy. patients were assessed at baseline and during follow up using photography, dermoscopy, salt score and regrowth scale.


Eligibility criteria:
inclusion criteria: * ِalopecia areata patients exclusion criteria: * alopecia totalis and universalis * ِage less than four years. * ِpregnancy or breast-feeding. * ِactive infection at the site alopecia patch(s). * ِinflammation ate site of the alopecia patches * ِintolerance to cold. * ِassociated systemic illness such as thyroid, pernicious anaemia, diabetes mellitus, autoimmune connective tissue diseases. * ِprevious treatment for alopecia areata over the last three months.

Keywords: alopecia areata microneedling cryotherapy
the assessment of talar cartilage in patients with unilateral traumatic transtibial amputation

Conditions: Traumatic Amputation of Lower Extremity; Cartilage Degeneration

Summary: increased risk of osteoarthritis (oa) has been previously demonstrated in patients with lower limb amputation. although there are many studies on knee joint of intact limb of amputees in the literature, the number of studies on intact foot and ankle is extremely limited. the primary aim of the study is to compare the intact talar cartilage, tibialis anterior and gastrocnemius muscle thickness measurements of traumatic unilateral transtibial amputee patients with that of healthy individuals using ultrasound. the secondary aim is to investigate the relationship between cartilage and muscle thickness measurements with clinical parameters.

methods: a total of 36 patients with unilateral transtibial amputations and 36 age and body mass index (bmi)-matched male controls will be participated in this cross-sectional study. functional performance will be assessed by 6-minute walking distance (in meter). the foot and ankle outcome score (faos) will be used for the assessment of the symptoms and the functional limitations of the foot and ankle. the health-related quality of life of the subjects will be evaluated with short form-36 (sf-36). subjects' talar cartilage, tibialis anterior and gastrocnemius muscle thickness measurements will be performed using musculoskeletal ultrasound.

Eligibility criteria:
inclusion criteria: * patients between the ages of 18-65 * patients who have been followed up for at least 3 months with the diagnosis of unilateral transtibial amputation * patients who have been using prostheses for at least 3 months exclusion criteria: * bilateral amputation * previous history of any trauma/surgical history of the lower extremities (other than amputation) * rheumatic diseases * contracture of the knee and the ankle of the intact limb

Keywords: amputation transtibial prosthesis cartilage muscle